HC Wainwright Reaffirms "Buy" Rating for XOMA (NASDAQ:XOMA)

XOMA (NASDAQ:XOMA - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $104.00 target price on the biotechnology company's stock. HC Wainwright's price objective points to a potential upside of 322.25% from the stock's current price. HC Wainwright also issued estimates for XOMA's Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.39 EPS, FY2025 earnings at $0.62 EPS and FY2026 earnings at $1.16 EPS.

A number of other brokerages have also weighed in on XOMA. Benchmark started coverage on shares of XOMA in a report on Thursday, April 17th. They issued a "buy" rating and a $35.00 price target for the company. Wall Street Zen raised shares of XOMA from a "sell" rating to a "hold" rating in a report on Friday, April 11th.

XOMA Price Performance

Shares of XOMA stock traded down $0.87 during midday trading on Wednesday, reaching $24.63. The company had a trading volume of 13,916 shares, compared to its average volume of 31,009. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The company has a market capitalization of $294.75 million, a price-to-earnings ratio of -7.08 and a beta of 0.89. The stock has a fifty day simple moving average of $22.93 and a 200 day simple moving average of $25.10. XOMA has a 1-year low of $18.35 and a 1-year high of $35.00.

XOMA (NASDAQ:XOMA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.32. The business had revenue of $15.91 million during the quarter, compared to analyst estimates of $6.75 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. As a group, equities research analysts forecast that XOMA will post -1.41 earnings per share for the current year.

Insider Buying and Selling at XOMA

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the firm's stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $27.10, for a total value of $10,642,793.30. Following the transaction, the insider now directly owns 1,267,545 shares of the company's stock, valued at approximately $34,350,469.50. This trade represents a 23.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Owen Hughes sold 25,637 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $25.38, for a total transaction of $650,667.06. Following the completion of the transaction, the chief executive officer now directly owns 62,701 shares in the company, valued at approximately $1,591,351.38. The trade was a 29.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have acquired 29,312 shares of company stock valued at $735,061. 9.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On XOMA

A number of hedge funds and other institutional investors have recently made changes to their positions in XOMA. Woodline Partners LP boosted its position in shares of XOMA by 63.9% during the fourth quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company's stock worth $4,107,000 after purchasing an additional 60,927 shares in the last quarter. Nuveen LLC bought a new position in shares of XOMA during the first quarter worth $286,000. CM Management LLC boosted its position in shares of XOMA by 16.4% during the first quarter. CM Management LLC now owns 64,000 shares of the biotechnology company's stock worth $1,276,000 after purchasing an additional 9,000 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of XOMA by 238.9% during the fourth quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company's stock worth $318,000 after purchasing an additional 8,522 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new position in shares of XOMA during the fourth quarter worth $206,000. 95.92% of the stock is owned by institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.